Tags

Type your tag names separated by a space and hit enter

Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Pol J Pathol. 2005; 56(3):107-10.PJ

Abstract

Gene expression analyses with cDNA microarray technology identified distinct groups of breast cancers. Tumors with no ER expression could be divided into three subgroups: "basal-like" subtype, HER2-positive subtype, and "normal breast-like". "Basal-like" subtype was characterized by high expression of keratins 5 and 17, laminin and fatty acid binding protein 7. In the present study, we analyzed the usefulness of immunohistochemistry for separation of the distinct subtypes of the breast ductal carcinomas and provided further characterization of "basal-like subtype". A consecutive series of 195 primary operable invasive breast carcinomas was immunostained for HER2, ER, PGR, CK5/6 and CK17. CK5/6 or CK17 were expressed in 72 cases (36.9%), and 41 cases (21%) presented expression of CK5/6 or CK17 without ER/PGR or HER2. ER/PGR was present in 109 cases (55.9%), but in this group there were 8 cases with HER2 overexpression and 17 cases with basal-cytokeratin positivity. Similarly, in 17 out of 72 "basal-like" tumors there was ER/PGR positivity, and also in 17 of them there was HER2 overexpression. Three of these cases belonged to all three groups, representing expression of all markers. Tumor grade differed significantly (p < 0.001) between luminal and basal cytokeratin- or HER2-positive tumors. Differences for tumor size and lymph node status were not statistically significant. Our study showed that immunohistochemistry is useful for dividing breast cancers into separate subgroups, but further analyses for better characterization of cases presenting two or three markers should be performed.

Authors+Show Affiliations

Department of Pathology, Chair of Oncology, Medical University of Lodz.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16334976

Citation

Kusińska, Renata, et al. "Immunohistochemical Identification of Basal-type Cytokeratins in Invasive Ductal Breast Carcinoma--relation With Grade, Stage, Estrogen Receptor and HER2." Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists, vol. 56, no. 3, 2005, pp. 107-10.
Kusińska R, Potemski P, Jesionek-Kupnicka D, et al. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2. Pol J Pathol. 2005;56(3):107-10.
Kusińska, R., Potemski, P., Jesionek-Kupnicka, D., & Kordek, R. (2005). Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2. Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists, 56(3), 107-10.
Kusińska R, et al. Immunohistochemical Identification of Basal-type Cytokeratins in Invasive Ductal Breast Carcinoma--relation With Grade, Stage, Estrogen Receptor and HER2. Pol J Pathol. 2005;56(3):107-10. PubMed PMID: 16334976.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2. AU - Kusińska,Renata, AU - Potemski,Piotr, AU - Jesionek-Kupnicka,Dorota, AU - Kordek,Radzisław, PY - 2005/12/13/pubmed PY - 2006/1/13/medline PY - 2005/12/13/entrez SP - 107 EP - 10 JF - Polish journal of pathology : official journal of the Polish Society of Pathologists JO - Pol J Pathol VL - 56 IS - 3 N2 - Gene expression analyses with cDNA microarray technology identified distinct groups of breast cancers. Tumors with no ER expression could be divided into three subgroups: "basal-like" subtype, HER2-positive subtype, and "normal breast-like". "Basal-like" subtype was characterized by high expression of keratins 5 and 17, laminin and fatty acid binding protein 7. In the present study, we analyzed the usefulness of immunohistochemistry for separation of the distinct subtypes of the breast ductal carcinomas and provided further characterization of "basal-like subtype". A consecutive series of 195 primary operable invasive breast carcinomas was immunostained for HER2, ER, PGR, CK5/6 and CK17. CK5/6 or CK17 were expressed in 72 cases (36.9%), and 41 cases (21%) presented expression of CK5/6 or CK17 without ER/PGR or HER2. ER/PGR was present in 109 cases (55.9%), but in this group there were 8 cases with HER2 overexpression and 17 cases with basal-cytokeratin positivity. Similarly, in 17 out of 72 "basal-like" tumors there was ER/PGR positivity, and also in 17 of them there was HER2 overexpression. Three of these cases belonged to all three groups, representing expression of all markers. Tumor grade differed significantly (p < 0.001) between luminal and basal cytokeratin- or HER2-positive tumors. Differences for tumor size and lymph node status were not statistically significant. Our study showed that immunohistochemistry is useful for dividing breast cancers into separate subgroups, but further analyses for better characterization of cases presenting two or three markers should be performed. SN - 1233-9687 UR - https://www.unboundmedicine.com/medline/citation/16334976/Immunohistochemical_identification_of_basal_type_cytokeratins_in_invasive_ductal_breast_carcinoma__relation_with_grade_stage_estrogen_receptor_and_HER2_ L2 - http://www.diseaseinfosearch.org/result/9738 DB - PRIME DP - Unbound Medicine ER -